FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1910-1916 December 28, 2000 Number 26 Next

Abstract PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and assessed their prognostic implications.

Methods Mononuclear cells from the blood of 325 patients with chronic lymphocytic leukemia were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 6q21, 11q22–23, 13q14, and 17p13; trisomy of bands 3q26, 8q24, and 12q13; and translocations involving band 14q32. Molecular cytogenetic data were correlated with clinical findings.

Results Chromosomal aberrations were detected in 268 of 325 cases (82 percent). The most frequent changes were a deletion in 13q (55 percent), a deletion in 11q (18 percent), trisomy of 12q (16 percent), a deletion in 17p (7 percent), and a deletion in 6q (6 percent). Five categories were defined with a statistical model: 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality; the median survival times for patients in these groups were 32, 79, 114, 111, and 133 months, respectively. Patients in the 17p- and 11q-deletion groups had more advanced disease than those in the other three groups. Patients with 17p deletions had the shortest median treatment-free interval (9 months), and those with 13q deletions had the longest (92 months). In multivariate analysis, the presence or absence of a 17p deletion, the presence or absence of an 11q deletion, age, Binet stage, the serum lactate dehydrogenase level, and the white-cell count gave significant prognostic information.

Conclusions Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival. These findings have implications for the design of risk-adapted treatment strategies.

There is considerable interest in identifying chromosomal aberrations that could pinpoint subgroups of patients with chronic lymphocytic leukemia who have different prognoses.⁵ Conventional cytogenetic analysis has been hampered by the low mitotic activity of the leukemic cells in vitro. With the usual method, clonal chromosomal aberrations are detected in only 40 to 50 percent of cases, the most common being trisomy 12 and abnormalities of chromosome bands 13q14 and 14q32.⁶ Fluorescence in situ hybridization allows the detection of chromosomal aberrations not only in dividing cells but also in interphase nuclei, an approach referred to as interphase cytogenetics. Initial studies of chronic lymphocytic leukemia with this method demonstrated that the frequency and spectrum of chromosomal aberrations it detected differed considerably from the results obtained by conventional chromosome banding.⁷ However, in these studies only single aberrations were evaluated for their prognostic importance, and this was done mostly in small series of patients.

We designed a comprehensive set of DNA probes for evaluating genomic changes in chronic lymphocytic leukemia by interphase cytogenetics. Our objective was to assess the frequency and clinical relevance of genomic aberrations in a large group of patients with the disease.

Methods

Patients

Between October 1990 and August 1998, 325 consecutive patients with chronic lymphocytic leukemia from a single institution were enrolled in the study and followed with regard to survival. There were 199 men and 126 women; their ages at the time of enrollment ranged from 30 to 87 years (median, 62). The diagnosis of chronic lymphocytic leukemia required persistent lymphocytosis (>5000 lymphocytes per cubic millimeter).⁸ Immunophenotypic data, available for 314 of the 325 patients, showed that all the cases of leukemia were CD19+, 298 of 308 tested were CD5+, and 300 of 308 tested were CD23+. All these cases were therefore of the B-cell type. At the time of enrollment, 63 patients were at Rai stage 0, 48 at stage 1, 146 at stage 2, 33 at stage 3, and 34 at stage 4.² According to the Binet system, 170 patients had stage A, 102 stage B, and 52 stage C disease.³ In one patient, clinical data were incomplete. Two hundred forty-eight patients had received no previous treatment, 39 patients had received one chemotherapeutic regimen, and 38 patients had received two or more chemotherapeutic regimens before interphase cytogenetic analysis. The median time from the date of diagnosis to the date of interphase cytogenetic study was 15 months (interquartile range, 1 to 43 months).

Interphase Cytogenetic Analysis

            DNA Probes

A set of DNA probes was developed to diagnose genomic aberrations by interphase cytogenetics. Chromosomal regions were selected on the basis of data from conventional chromosome-banding studies and comparative genomic hybridization.^6,9 The DNA probes allowed us to screen for the following partial deletions, partial trisomies, and translocations (the clone designation and the gene or locus detected are shown in brackets): +(3q26) [yeast artificial chromosome 866_e_7],¹⁰ del(6q21) [963_d_6],¹¹ +(8q24) [935_a_12],¹⁰ del(11q22–q23) [755_b_11],¹² +12q13 [754_a_1],¹⁰ and del(13q14) [-phage clones, which recognize RB1 (kindly provided by Dr. Thaddeus Dryja, Boston); cosmid c1325, which identifies D13S25],¹³ t(14q32) [cosmid cos-C_1/2, which recognizes the c₁ and c₂ gene segments proximal to the J_H region; yeast artificial chromosome Y6, which identifies V_H segments telomeric to the J_H break points in the immunoglobulin heavy-chain gene (IgH)],¹² and del(17p13) [cosmids ICRFc105BO195–75, ICRFc105CO275–77, ICRFc105EO675–78, and ICRFc105AO144–79 for p53].¹⁴

In cases showing splitting of one fluorescence signal with the IgH probes, the leukemia cells were analyzed for two reciprocal translocations: t(11;14) and t(14;18). For the diagnosis of t(11;14), the IgH probes were combined with the differently labeled 540-kb yeast artificial chromosome 55_g_7, which recognizes DNA sequences spanning the region between the major translocation cluster and the CCND1 gene in the BCL1 locus at 11q13¹²; for the detection of t(14;18), the IgH probes were combined with yeast artificial chromosome yA153_A_6, which spans the BCL2 proto-oncogene (kindly provided by G. Silverman, Boston).

            Detection of Genomic Aberrations by Fluorescence in Situ Hybridization

DNA probe sequences from yeast artificial chromosome clones were generated by an inter-Alu polymerase-chain-reaction (PCR) protocol.¹⁵ Cosmid DNA was prepared according to the plasmid Midi Kit protocol (Qiagen, Hilden, Germany). The probes were labeled by nick translation with biotin–16-deoxyuridine triphosphate or digoxigenin–11-deoxyuridine triphosphate (Roche, Mannheim, Germany). Fluorescence in situ hybridization was performed as described previously.^12,14

Statistical Analysis

The primary end point was survival from the time of diagnosis. Survival times and censored waiting times measured from the date of diagnosis were plotted with the use of Kaplan–Meier estimates. The median duration of follow-up was calculated according to the method of Korn.¹⁶ The proportional-hazards regression model of Cox was used to identify differences in survival due to prognostic factors.¹⁷ As possible prognostic factors, age, sex, Binet and Rai stages, hemoglobin level, white-cell count, platelet count, serum lactate dehydrogenase and alkaline phosphatase levels, presence or absence of splenomegaly and lymphadenopathy, extent of peripheral lymphadenopathy, greatest lymph-node diameter measured, and presence or absence of genomic aberrations (deletion in 17p, deletion in 11q, trisomy of 12q, deletion in 13q, and deletion in 6q) were included in the regression model. We estimated missing data using a multiple-imputation technique with 10 random draws. A limited backward-selection procedure was used to exclude redundant or unnecessary variables.¹⁸

Groupwise comparisons of the distributions of clinical and laboratory variables at the time of the genetic study were performed with the Kruskal–Wallis test (for quantitative variables) and Fisher's exact test (for categorical variables). All tests were two-sided. An effect was considered statistically significant if the P value was 0.05 or less. To provide quantitative information on the relevance of statistically significant results, 95 percent confidence intervals for hazard ratios were computed. The statistical analyses were performed with the following software packages: StatXact (Cytel Software, Cambridge, Mass.), S-Plus (MathSoft, Seattle), and the Design software library.¹⁸

Results

Interphase Cytogenetic Analysis

All 325 cases could be evaluated by interphase cytogenetics. Of these cases, 268 (82 percent) exhibited abnormalities. Table 1 lists these aberrations, in order of decreasing frequency. In 175 patients there was one aberration, 67 patients had two aberrations, and 26 patients had more than two aberrations. Among the 178 patients with 13q deletion, the deletion was the sole abnormality in 117 (66 percent). In the remaining 61 patients (34 percent), 13q deletion was accompanied by 11q deletion (28 patients), 12q trisomy (13 patients), 11q deletion and 12q trisomy (1 patient), 17p deletion (8 patients), or other abnormalities (11 patients). An 11q deletion occurred as the sole aberration in 19 of 58 patients (33 percent), 12q trisomy in 22 of 53 patients (42 percent), 17p deletion in 4 of 23 patients (17 percent), and 6q deletion in 6 of 21 patients (29 percent). All deletions were monoallelic except for the 13q14 region: in 43 of the 178 patients with 13q deletions (24 percent), there were biallelic or concomitant monoallelic and biallelic deletions. In all cases, biallelic deletion affected the D13S25 locus, and in 2 of the 43 patients there was also biallelic RB1 deletion. Of the 12 patients with the translocation t(14q32), 7 had t(14;18), and the rest had t(14q32) with an unidentified partner. We included patients with t(14;18) in the analysis, since they had the typical morphologic features and immunophenotype of chronic lymphocytic leukemia. No patient had t(11;14).

View this table: [in this window] [in a new window]   Table 1. Incidence of Chromosomal Abnormalities in 325 Patients with Chronic Lymphocytic Leukemia.

 
Correlation with Clinical and Laboratory Data

The proportional-hazards regression model with backward selection identified six significant prognostic factors: 17p deletion (P<0.001), 11q deletion (P= 0.004), age (P<0.001), Binet stage (B as compared with A, P=0.36; C as compared with A, P=0.002), serum lactate dehydrogenase level (P=0.002), and white-cell count (P=0.02). There was a statistically significant interaction effect between age and the presence or absence of an 11q deletion (P=0.02): the negative prognostic effect of an 11q deletion was seen primarily in younger patients. The hazard ratios together with their 95 percent confidence limits are shown in Table 2.

View this table: [in this window] [in a new window]   Table 2. Results of Cox Regression Analysis of Survival Time from Diagnosis (Final Model).

 
On the basis of the regression analysis, we constructed a hierarchical model of genetic subgroups in which each case was allocated to one category only. Table 3 lists the five major categories to which 300 of the 325 cases could be assigned with this model.

View this table: [in this window] [in a new window]   Table 3. Hierarchical Model of Chromosomal Abnormalities in Chronic Lymphocytic Leukemia.

 
After a median follow-up of 70 months, 112 of the 325 patients had died. The median survival time of the entire group was 108 months (95 percent confidence interval, 94 to 119). The estimated median survival times from the date of diagnosis for the five genetic categories listed in Table 3 were as follows: 17p deletion, 32 months; 11q deletion, 79 months; 12q trisomy, 114 months; normal karyotype, 111 months; and 13q deletion as the sole abnormality, 133 months (Figure 1). The remaining 25 patients were combined into the group with various abnormalities. This heterogeneous group included patients with 3q trisomy, 6q deletion, 8q trisomy, or t(14q32). Patients in this category had a high probability of survival (the median survival time was not reached).

View larger version (27K): [in this window] [in a new window]   Figure 1. Probability of Survival from the Date of Diagnosis among the Patients in the Five Genetic Categories. The median survival times for the groups with 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality were 32, 79, 114, 111, and 133 months, respectively. Twenty-five patients with various other chromosomal abnormalities are not included in the analysis.

 
Table 4 shows the clinical and laboratory data for the patients in the five major categories at the time of enrollment. Patients with 17p or 11q deletions had more advanced disease than those in the other three groups (P<0.001), whereas patients with 13q deletions had the highest proportion at Binet stage A (72 percent). The groups with 17p and 11q deletions were more likely to have splenomegaly, mediastinal lymphadenopathy, and abdominal lymphadenopathy and had more extensive peripheral lymphadenopathy. The extent of lymph-node involvement was particularly striking in the 11q-deletion group. Moreover, patients with 11q and 17p deletions were more likely than the others to have fever, night sweats, or weight loss (B symptoms) and had lower hemoglobin values and lower platelet counts; patients with 17p deletions had higher serum lactate dehydrogenase and alkaline phosphatase levels and lower serum albumin levels.

View this table: [in this window] [in a new window]   Table 4. Comparison of Clinical and Laboratory Data among the Major Cytogenetic Subgroups.

 
There were statistically significant differences in disease progression among the five genetic categories, as indicated by the treatment-free interval (Figure 2). Patients in the groups with 17p and 11q deletions had more rapid disease progression: the median time from the date of diagnosis to the date of first treatment in these two groups was only 9 and 13 months, respectively, and eventually all these patients required therapy. The median treatment-free interval was longer in the 12q-trisomy group (33 months) and the normal-karyotype group (49 months), and it was the longest by far in the 13q-deletion group (92 months). In the last group, nearly one third of the patients did not require therapy.

View larger version (25K): [in this window] [in a new window]   Figure 2. Probability of Disease Progression, as Indicated by the Treatment-free Interval in the Patients in the Five Genetic Categories. The median treatment-free intervals for the groups with 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality were 9, 13, 33, 49, and 92 months, respectively. The differences between the curves were significant (P<0.001). Twenty-five patients with various other chromosomal abnormalities are not included in the analysis.

 
Discussion

We found that molecular cytogenetic methods can detect genomic aberrations in over 80 percent of patients with chronic lymphocytic leukemia, or about twice as frequently as chromosome banding.⁵ The most frequent abnormality we found was a deletion involving chromosome band 13q14, which occurred in 55 percent of cases. This result is consistent with studies using microsatellite and quantitative Southern blot analysis.^13,19,20,21 The second-most-frequent change was a deletion in 11q (found in 18 percent of patients). Previous evidence from banding studies of chromosomal loss from 11q in chronic lymphocytic leukemia is inconsistent.^5,22 Sixteen percent of our patients had 12q trisomy, which was long considered the most frequent chromosomal abnormality in chronic lymphocytic leukemia; in our study it was the third most frequent aberration.

Little is known about the molecular correlates of these chromosomal abnormalities. The tumor suppressor gene p53 is affected by 17p deletions.^14,23 Recent studies suggest that the gene encoding the ataxia–telangiectasia mutated protein is altered in some cases of chronic lymphocytic leukemia with 11q deletion.^24,25,26 Band 13q14 probably contains a tumor-suppressor gene with a role in chronic lymphocytic leukemia.^13,19,20,21 No disease-related genes have yet been associated with the other aberrations.

These aberrations are among the most important factors in predicting survival. Patients with 17p deletions had by far the worst prognosis, followed by patients with 11q deletions, those with 12q trisomy, and those with normal karyotypes, whereas patients with 13q deletions as the sole abnormality had the longest estimated survival times (Figure 1). These observations parallel the more frequent finding of advanced disease at enrollment in patients with 17p or 11q deletions. In a smaller series of patients, extensive lymphadenopathy was particularly striking in patients with an 11q deletion.¹² In the multivariate analysis, both 17p deletion and 11q deletion provided statistically significant prognostic information, with 17p deletion being the strongest predictor of poor survival.

Most previous studies of chromosomal aberrations in chronic lymphocytic leukemia did not identify chromosomal abnormalities that provided independent prognostic information.⁶ The poor prognosis of patients with 17p deletion or p53 mutation has been reported in only a few studies.^14,23,27 El Rouby et al. found that mutation of p53 was the strongest independent prognostic factor.²³ In a prospective study using chromosome banding, abnormality of chromosome 17 was associated with poor survival, and it was the only cytogenetic finding with independent prognostic value.²⁷ Neilson et al. found that 11q deletions were associated with rapid disease progression and shorter survival times.²² The prognostic effect of 12q trisomy has been controversial^5,6,28,29; our data indicate that patients with 12q trisomy have shorter survival than those who have a 13q deletion as the sole aberration. The finding of a favorable outcome for patients with 13q deletions supports other data.⁶

Two recent studies further illuminate the biologic basis of the clinical variability of chronic lymphocytic leukemia.^30,31 They indicate that chronic lymphocytic leukemia can arise at different stages of B-cell maturation, as indicated by the presence or absence of mutations of immunoglobulin variable genes: the latter represents naive B cells before they enter the germinal center, and the former memory B cells that have passed through germinal centers. Patients with chronic lymphocytic leukemia originating from naive B cells had significantly shorter survival than patients with chronic lymphocytic leukemia arising from memory B cells. It will be necessary to assess the relative prognostic value of the currently used clinical, biochemical, and genetic markers in large, prospective trials. Our results with molecular cytogenetic techniques may already have implications for the risk-adapted clinical management of chronic lymphocytic leukemia, particularly in younger patients.

Supported by grants from the Deutsche Krebshilfe (70-2434-Dö I and 10-1289-St I), the European Community (QLGZ-1999-CT 00786), and the Tumorzentrum Heidelberg–Mannheim (I/I.1 and I/I.2).

We are indebted to Kathrin Wildenberger, Edeltraud Weilguni, and Petra Schramm for technical assistance and to Dr. Lutz Edler for statistical advice.

Source Information

From the Department of Internal Medicine III University of Ulm, Ulm (H.D., S.S., E.L., A.K., L.B., K.D., M.B.); and the Deutsches Krebsforschungszentrum, Heidelberg (A.B., P.L.) — both in Germany.

Address reprint requests to Dr. Hartmut Döhner at the Department of Internal Medicine III, University of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany, or at hartmut.doehner{at}medizin.uni-ulm.de.

References

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057. [Erratum, N Engl J Med 1995;333:1515.] [Free Full Text]
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234. [Free Full Text]
3. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206. [CrossRef][Medline]
4. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998;25:42-59. [Medline]
5. Juliusson G, Merup M. Cytogenetics in chronic lymphocytic leukemia. Semin Oncol 1998;25:19-26. [Medline]
6. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724. [Abstract]
7. Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266-281. [CrossRef][Medline]
8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. [Free Full Text]
9. Bentz M, Huck K, du Manoir S. et al. Comparative genomic hybridization in chronic B-cell leukemias reveals a high incidence of chromosomal gains and losses. Blood 1995;85:3610-3618. [Free Full Text]
10. Bentz M, Plesch A, Bullinger L, et al. t(11;14)-Positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemias. Genes Chromosomes Cancer 2000;27:285-294. [CrossRef][Medline]
11. Stilgenbauer S, Bullinger L, Benner A, et al. Incidence and prognostic significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999;13:1331-1334. [CrossRef][Medline]
12. Döhner H, Stilgenbauer S, James MR, et al. 11q Deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522. [Free Full Text]
13. Stilgenbauer S, Nickolenko J, Wilhelm J, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene 1998;16:1891-1897. [CrossRef][Medline]
14. Döhner H, Fischer K, Bentz M, et al. p53 Gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-1589. [Free Full Text]
15. Lengauer C, Green ED, Cremer T. Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. Genomics 1992;13:826-828. [CrossRef][Medline]
16. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986;5:255-260. [Medline]
17. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
18. Harrell FE. Predicting outcome: applied survival analysis and logistic regression. Charlottesville: University of Virginia, 1998.
19. Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 1997;42:369-377. [CrossRef][Medline]
20. Liu Y, Corcoran M, Rasool O, et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997;15:2463-2473. [CrossRef][Medline]
21. Bullrich F, Veronese ML, Kitada S, et al. Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 1996;88:3109-3115. [Free Full Text]
22. Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:1929-1932. [CrossRef][Medline]
23. el Rouby S, Thomas A, Costin D, et al. p53 Gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-3459. [Free Full Text]
24. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26-29. [CrossRef][Medline]
25. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999;59:24-27. [Free Full Text]
26. Schaffner C, Stilgenbauer S, Rappold G, Döhner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94:748-753. [Free Full Text]
27. Geisler CH, Philip P, Christensen BE, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997;21:1011-1023. [CrossRef][Medline]
28. Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 1990;76:352-358. [Medline]
29. Escudier SM, Pereira-Leahy JM, Drach JW, et al. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993;81:2702-2707. [Free Full Text]
30. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. [Free Full Text]
31. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V_H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. [Free Full Text]

Abstract PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This article has been cited by other articles:

• Quijano, S., Lopez, A., Rasillo, A., Barrena, S., Luz Sanchez, M., Flores, J., Fernandez, C., Sayagues, J. M., Osuna, C. S., Fernandez, N., Gonzalez, M., Giraldo, P., Giralt, M., Perez, M. C., Martin-Antoran, J. M., Gutierrez, O., Perdiguer, L., Diaz Mediavilla, J., Gonzalez Silva, M., Asensio del Rio, A., Cervero, C., Guerra, J. L., Butron, R., del Carmen Garcia, M., Almeida, J., Orfao, A. (2008). Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood 111: 5130-5141 [Abstract] [Full Text]  
• Shanafelt, T. D., Hanson, C., Dewald, G. W., Witzig, T. E., LaPlant, B., Abrahamzon, J., Jelinek, D. F., Kay, N. E. (2008). Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression. JCO 26: e5-e6 [Full Text]  
• Sander, S., Bullinger, L., Leupolt, E., Benner, A., Kienle, D., Katzenberger, T., Kalla, J., Ott, G., Muller-Hermelink, H. K., Barth, T. F.E., Moller, P., Lichter, P., Dohner, H., Stilgenbauer, S. (2008). Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. haematol 93: 680-687 [Abstract] [Full Text]  
• Hewamana, S., Alghazal, S., Lin, T. T., Clement, M., Jenkins, C., Guzman, M. L., Jordan, C. T., Neelakantan, S., Crooks, P. A., Burnett, A. K., Pratt, G., Fegan, C., Rowntree, C., Brennan, P., Pepper, C. (2008). The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111: 4681-4689 [Abstract] [Full Text]  
• Athanasiadou, A., Stamatopoulos, K., Gaitatzi, M., Stavroyianni, N., Fassas, A., Anagnostopoulos, A. (2008). Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. haematol 93: 473-474 [Abstract] [Full Text]  
• Agrawal, S. G., Liu, F.-T., Wiseman, C., Shirali, S., Liu, H., Lillington, D., Du, M.-Q., Syndercombe-Court, D., Newland, A. C., Gribben, J. G., Jia, L. (2008). Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood 111: 2790-2796 [Abstract] [Full Text]  
• Ouillette, P., Erba, H., Kujawski, L., Kaminski, M., Shedden, K., Malek, S. N. (2008). Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14. Cancer Res. 68: 1012-1021 [Abstract] [Full Text]  
• Roos, G., Krober, A., Grabowski, P., Kienle, D., Buhler, A., Dohner, H., Rosenquist, R., Stilgenbauer, S. (2008). Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 111: 2246-2252 [Abstract] [Full Text]  
• Gachard, N., Salviat, A., Boutet, C., Arnoulet, C., Durrieu, F., Lenormand, B., Lepretre, S., Olschwang, S., Jardin, F., Lafage-Pochitaloff, M., Penther, D., Sainty, D., Reminieras, L., Feuillard, J., Bene, M. C., for the GEIL, (2008). Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. haematol 93: 215-223 [Abstract] [Full Text]  
• Saddler, C., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., Erba, H., Shedden, K., Wang, S., Malek, S. N. (2008). Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111: 1584-1593 [Abstract] [Full Text]  
• Sellick, G. S., Wade, R., Richards, S., Oscier, D. G., Catovsky, D., Houlston, R. S. (2008). Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 111: 1625-1633 [Abstract] [Full Text]  
• Gattei, V., Bulian, P., Del Principe, M. I., Zucchetto, A., Maurillo, L., Buccisano, F., Bomben, R., Dal-Bo, M., Luciano, F., Rossi, F. M., Degan, M., Amadori, S., Del Poeta, G. (2008). Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111: 865-873 [Abstract] [Full Text]  
• Hauswirth, A. W., Jager, U. (2008). Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. haematol 93: 14-19 [Full Text]  
• Gine, E., Crespo, M., Muntanola, A., Calpe, E., Baptista, M. J., Villamor, N., Montserrat, E., Bosch, F. (2008). Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. haematol 93: 75-82 [Abstract] [Full Text]  
• Bosch, F., Ferrer, A., Villamor, N., Gonzalez, M., Briones, J., Gonzalez-Barca, E., Abella, E., Gardella, S., Escoda, L., Perez-Ceballos, E., Asensi, A., Sayas, M. J., Font, L., Altes, A., Muntanola, A., Bertazzoni, P., Rozman, M., Aymerich, M., Gine, E., Montserrat, E. (2008). Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clin. Cancer Res. 14: 155-161 [Abstract] [Full Text]  
• Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B., Dmoszynska, A., Wu, J., Sirard, C., Mayer, J. (2007). Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. JCO 25: 5616-5623 [Abstract] [Full Text]  
• Austen, B., Skowronska, A., Baker, C., Powell, J. E., Gardiner, A., Oscier, D., Majid, A., Dyer, M., Siebert, R., Taylor, A. M., Moss, P. A., Stankovic, T. (2007). Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion. JCO 25: 5448-5457 [Abstract] [Full Text]  
• Santidrian, A. F., Cosialls, A. M., Coll-Mulet, L., Iglesias-Serret, D., de Frias, M., Gonzalez-Girones, D. M., Campas, C., Domingo, A., Pons, G., Gil, J. (2007). The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells. haematol 92: 1631-1638 [Abstract] [Full Text]  
• Damle, R. N., Temburni, S., Calissano, C., Yancopoulos, S., Banapour, T., Sison, C., Allen, S. L., Rai, K. R., Chiorazzi, N. (2007). CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110: 3352-3359 [Abstract] [Full Text]  
• Tsimberidou, A. M., Wen, S., O'Brien, S., McLaughlin, P., Wierda, W. G., Ferrajoli, A., Faderl, S., Manning, J., Lerner, S., Mai, C. V., Rodriguez, A. M., Hess, M., Do, K.-A., Freireich, E. J., Kantarjian, H. M., Medeiros, L. J., Keating, M. J. (2007). Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center. JCO 25: 4648-4656 [Abstract] [Full Text]  
• Willimott, S., Baou, M., Huf, S., Deaglio, S., Wagner, S. D. (2007). Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. haematol 92: 1359-1366 [Abstract] [Full Text]  
• Durig, J., Ebeling, P., Grabellus, F., Sorg, U. R., Mollmann, M., Schutt, P., Gothert, J., Sellmann, L., Seeber, S., Flasshove, M., Duhrsen, U., Moritz, T. (2007). A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease. Cancer Res. 67: 8653-8661 [Abstract] [Full Text]  
• Joshi, A. D., Hegde, G. V., Dickinson, J. D., Mittal, A. K., Lynch, J. C., Eudy, J. D., Armitage, J. O., Bierman, P. J., Bociek, R. G., Devetten, M. P., Vose, J. M., Joshi, S. S. (2007). ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38 Expressing B-Cell Chronic Lymphocytic Leukemia. Clin. Cancer Res. 13: 5295-5304 [Abstract] [Full Text]  
• Stilgenbauer, S., Sander, S., Bullinger, L., Benner, A., Leupolt, E., Winkler, D., Krober, A., Kienle, D., Lichter, P., Dohner, H. (2007). Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. haematol 92: 1242-1245 [Abstract] [Full Text]  
• Ross, C. W., Ouillette, P. D., Saddler, C. M., Shedden, K. A., Malek, S. N. (2007). Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis. Clin. Cancer Res. 13: 4777-4785 [Abstract] [Full Text]  
• Kienle, D., Katzenberger, T., Ott, G., Saupe, D., Benner, A., Kohlhammer, H., Barth, T. F.E., Holler, S., Kalla, J., Rosenwald, A., Muller-Hermelink, H. K., Moller, P., Lichter, P., Dohner, H., Stilgenbauer, S. (2007). Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors. JCO 25: 2770-2777 [Abstract] [Full Text]  
• Raveche, E. S., Salerno, E., Scaglione, B. J., Manohar, V., Abbasi, F., Lin, Y.-C., Fredrickson, T., Landgraf, P., Ramachandra, S., Huppi, K., Toro, J. R., Zenger, V. E., Metcalf, R. A., Marti, G. E. (2007). Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109: 5079-5086 [Abstract] [Full Text]  
• Sabattini, E., Orduz, R., Campidelli, C., Zinzani, P. L., Callea, V., Zupo, S., Cutrona, G., Morabito, F., Ferrarini, M., Pileri, S. (2007). B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. J. Clin. Pathol. 60: 627-632 [Abstract] [Full Text]  
• Josefsson, P., Geisler, C. H., Leffers, H., Petersen, J. H., Andersen, M. K., Jurlander, J., Buhl, A. M. (2007). CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 109: 4973-4979 [Abstract] [Full Text]  
• Wierda, W. G., O'Brien, S., Wang, X., Faderl, S., Ferrajoli, A., Do, K.-A., Cortes, J., Thomas, D., Garcia-Manero, G., Koller, C., Beran, M., Giles, F., Ravandi, F., Lerner, S., Kantarjian, H., Keating, M. (2007). Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109: 4679-4685 [Abstract] [Full Text]  
• Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N., Tavolaro, S., Castellano, L., Magrelli, A., Citarella, F., Messina, M., Maggio, R., Peragine, N., Santangelo, S., Mauro, F. R., Landgraf, P., Tuschl, T., Weir, D. B., Chien, M., Russo, J. J., Ju, J., Sheridan, R., Sander, C., Zavolan, M., Guarini, A., Foa, R., Macino, G. (2007). Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109: 4944-4951 [Abstract] [Full Text]  
• Vallat, L. D., Park, Y., Li, C., Gribben, J. G. (2007). Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood 109: 3989-3997 [Abstract] [Full Text]  
• Muntanola, A., Bosch, F., Arguis, P., Arellano-Rodrigo, E., Ayuso, C., Gine, E., Crespo, M., Abrisqueta, P., Moreno, C., Cobo, F., Lopez-Guillermo, A., Montserrat, E. (2007). Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia. JCO 25: 1576-1580 [Abstract] [Full Text]  
• Wolff, D. J., Bagg, A., Cooley, L. D., Dewald, G. W., Hirsch, B. A., Jacky, P. B., Rao, K. W., Rao, P. N., the Association for Molecular Pathology Clinical P, (2007). Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders. J. Mol. Diagn. 9: 134-143 [Abstract] [Full Text]  
• Grever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., Reed, J. C., Kitada, S., Flinn, I. W., Tallman, M. S., Appelbaum, F. R., Larson, R. A., Paietta, E., Jelinek, D. F., Gribben, J. G., Byrd, J. C. (2007). Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. JCO 25: 799-804 [Abstract] [Full Text]  
• Wlodarska, I., Matthews, C., Veyt, E., Pospisilova, H., Catherwood, M. A., Poulsen, T. S., Vanhentenrijk, V., Ibbotson, R., Vandenberghe, P., Morris, T.C.M. C., Alexander, H. D. (2007). Telomeric IGH Losses Detectable by Fluorescence in Situ Hybridization in Chronic Lymphocytic Leukemia Reflect Somatic VH Recombination Events. J. Mol. Diagn. 9: 47-54 [Abstract] [Full Text]  
• Ng, D., Toure, O., Wei, M.-H., Arthur, D. C., Abbasi, F., Fontaine, L., Marti, G. E., Fraumeni, J. F. Jr, Goldin, L. R., Caporaso, N., Toro, J. R. (2007). Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood 109: 916-925 [Abstract] [Full Text]  
• Pfeifer, D., Pantic, M., Skatulla, I., Rawluk, J., Kreutz, C., Martens, U. M., Fisch, P., Timmer, J., Veelken, H. (2007). Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109: 1202-1210 [Abstract] [Full Text]  
• Venugopal, P., Gregory, S. A. (2007). Lymphoproliferative disorders. ASH-SAP 2007: 265-297 [Full Text]  
• Nuckel, H., Frey, U. H., Bau, M., Sellmann, L., Stanelle, J., Durig, J., Jockel, K.-H., Duhrsen, U., Siffert, W. (2007). Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 109: 290-297 [Abstract] [Full Text]  
• Pekarsky, Y., Santanam, U., Cimmino, A., Palamarchuk, A., Efanov, A., Maximov, V., Volinia, S., Alder, H., Liu, C.-G., Rassenti, L., Calin, G. A., Hagan, J. P., Kipps, T., Croce, C. M. (2006). Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181. Cancer Res. 66: 11590-11593 [Abstract] [Full Text]  
• Ghesquieres, H., Berger, F., Felman, P., Callet-Bauchu, E., Bryon, P.-A., Traverse-Glehen, A., Thieblemont, C., Baseggio, L., Michallet, A.-S., Coiffier, B., Salles, G. (2006). Clinicopathologic Characteristics and Outcome of Diffuse Large B-Cell Lymphomas Presenting With an Associated Low-Grade Component at Diagnosis. JCO 24: 5234-5241 [Abstract] [Full Text]  
• Tinhofer, I., Rubenzer, G., Holler, C., Hofstaetter, E., Stoecher, M., Egle, A., Steurer, M., Greil, R. (2006). Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 108: 2950-2956 [Abstract] [Full Text]  
• Dicker, F., Schnittger, S., Haferlach, T., Kern, W., Schoch, C. (2006). Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 108: 3152-3160 [Abstract] [Full Text]  
• Shanafelt, T. D., Witzig, T. E., Fink, S. R., Jenkins, R. B., Paternoster, S. F., Smoley, S. A., Stockero, K. J., Nast, D. M., Flynn, H. C., Tschumper, R. C., Geyer, S., Zent, C. S., Call, T. G., Jelinek, D. F., Kay, N. E., Dewald, G. W. (2006). Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia. JCO 24: 4634-4641 [Abstract] [Full Text]  
• Frey, U. H., Nuckel, H., Sellmann, L., Siemer, D., Kuppers, R., Durig, J., Duhrsen, U., Siffert, W. (2006). The GNAS1 T393C Polymorphism Is Associated with Disease Progression and Survival in Chronic Lymphocytic Leukemia.. Clin. Cancer Res. 12: 5686-5692 [Abstract] [Full Text]  
• Shanafelt, T. D., Byrd, J. C., Call, T. G., Zent, C. S., Kay, N. E. (2006). Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.. ANN INTERN MED 145: 435-447 [Abstract] [Full Text]  
• Zenz, T., Ritgen, M., Dreger, P., Krober, A., Barth, T. F., Schlenk, R., Bottcher, S., Hallek, M. J., Kneba, M., Bunjes, D., Dohner, H., Stilgenbauer, S. (2006). Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 108: 2127-2130 [Abstract] [Full Text]  
• Yan, X.-j., Albesiano, E., Zanesi, N., Yancopoulos, S., Sawyer, A., Romano, E., Petlickovski, A., Efremov, D. G., Croce, C. M., Chiorazzi, N. (2006). B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 103: 11713-11718 [Abstract] [Full Text]  
• Del Principe, M. I., Del Poeta, G., Buccisano, F., Maurillo, L., Venditti, A., Zucchetto, A., Marini, R., Niscola, P., Consalvo, M. A. I., Mazzone, C., Ottaviani, L., Panetta, P., Bruno, A., Bomben, R., Suppo, G., Degan, M., Gattei, V., de Fabritiis, P., Cantonetti, M., Lo Coco, F., Del Principe, D., Amadori, S. (2006). Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108: 853-861 [Abstract] [Full Text]  
• Coll-Mulet, L., Iglesias-Serret, D., Santidrian, A. F., Cosialls, A. M., de Frias, M., Castano, E., Campas, C., Barragan, M., de Sevilla, A. F., Domingo, A., Vassilev, L. T., Pons, G., Gil, J. (2006). MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107: 4109-4114 [Abstract] [Full Text]  
• Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., Zauli, G. (2006). Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107: 4122-4129 [Abstract] [Full Text]  
• Richardson, S. J., Matthews, C., Catherwood, M. A., Alexander, H. D., Carey, B. S., Farrugia, J., Gardiner, A., Mould, S., Oscier, D., Copplestone, J. A., Prentice, A. G. (2006). ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107: 3584-3592 [Abstract] [Full Text]  
• Thorselius, M., Krober, A., Murray, F., Thunberg, U., Tobin, G., Buhler, A., Kienle, D., Albesiano, E., Maffei, R., Dao-Ung, L.-P., Wiley, J., Vilpo, J., Laurell, A., Merup, M., Roos, G., Karlsson, K., Chiorazzi, N., Marasca, R., Dohner, H., Stilgenbauer, S., Rosenquist, R. (2006). Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 107: 2889-2894 [Abstract] [Full Text]  
• Buhl, A. M., Jurlander, J., Jorgensen, F. S., Ottesen, A. M., Cowland, J. B., Gjerdrum, L. M., Hansen, B. V., Leffers, H. (2006). Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood 107: 2904-2911 [Abstract] [Full Text]  
• Kienle, D., Benner, A., Krober, A., Winkler, D., Mertens, D., Buhler, A., Seiler, T., Jager, U., Lichter, P., Dohner, H., Stilgenbauer, S. (2006). Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 107: 2090-2093 [Abstract] [Full Text]  
• Krober, A., Bloehdorn, J., Hafner, S., Buhler, A., Seiler, T., Kienle, D., Winkler, D., Bangerter, M., Schlenk, R. F., Benner, A., Lichter, P., Dohner, H., Stilgenbauer, S. (2006). Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. JCO 24: 969-975 [Abstract] [Full Text]  
• Eichhorst, B. F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., Siehl, S., Jager, U., Bergmann, M., Stilgenbauer, S., Schweighofer, C., Wendtner, C. M., Dohner, H., Brittinger, G., Emmerich, B., Hallek, M., the German CLL Study Group, (2006). Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107: 885-891 [Abstract] [Full Text]  
• Binet, J.-L., Caligaris-Cappio, F., Catovsky, D., Cheson, B., Davis, T., Dighiero, G., Dohner, H., Hallek, M., Hillmen, P., Keating, M., Montserrat, E., Kipps, T. J., Rai, K., for the International Workshop on Chronic Lymphocy, (2006). Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107: 859-861 [Abstract] [Full Text]  
• Byrd, J. C., Gribben, J. G., Peterson, B. L., Grever, M. R., Lozanski, G., Lucas, D. M., Lampson, B., Larson, R. A., Caligiuri, M. A., Heerema, N. A. (2006). Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. JCO 24: 437-443 [Abstract] [Full Text]  
• Mayr, C., Speicher, M. R., Kofler, D. M., Buhmann, R., Strehl, J., Busch, R., Hallek, M., Wendtner, C.-M. (2006). Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107: 742-751 [Abstract] [Full Text]  
• Montserrat, E. (2006). New Prognostic Markers in CLL. ASH Education Book 2006: 279-284 [Abstract] [Full Text]  
• Abbott, B. L. (2006). Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment. The Oncologist 11: 21-30 [Abstract] [Full Text]  
• Gribben, J. G., Zahrieh, D., Stephans, K., Bartlett-Pandite, L., Alyea, E. P., Fisher, D. C., Freedman, A. S., Mauch, P., Schlossman, R., Sequist, L. V., Soiffer, R. J., Marshall, B., Neuberg, D., Ritz, J., Nadler, L. M. (2005). Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106: 4389-4396 [Abstract] [Full Text]  
• Nabhan, C., Bitran, J. D. (2005). Chronic Lymphocytic Leukemia: To Transplant or Not to Transplant... That Is the Question?. JCO 23: 8126-8127 [Full Text]  
• Marasca, R., Maffei, R., Morselli, M., Zucchini, P., Castelli, I., Martinelli, S., Fontana, M., Ravanetti, S., Curotti, M., Leonardi, G., Cagossi, K., Partesotti, G., Torelli, G. (2005). Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia. J. Mol. Diagn. 7: 566-574 [Abstract] [Full Text]  
• Caballero, D., Garcia-Marco, J. A., Martino, R., Mateos, V., Ribera, J. M., Sarra, J., Leon, A., Sanz, G., de la Serna, J., Cabrera, R., Gonzalez, M., Sierra, J., San Miguel, J. (2005). Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-). Clin. Cancer Res. 11: 7757-7763 [Abstract] [Full Text]  
• Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M., Iuliano, R., Palumbo, T., Pichiorri, F., Roldo, C., Garzon, R., Sevignani, C., Rassenti, L., Alder, H., Volinia, S., Liu, C.-g., Kipps, T. J., Negrini, M., Croce, C. M. (2005). A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. NEJM 353: 1793-1801 [Abstract] [Full Text]  
• Oppezzo, P., Vasconcelos, Y., Settegrana, C., Jeannel, D., Vuillier, F., Legarff-Tavernier, M., Kimura, E. Y., Bechet, S., Dumas, G., Brissard, M., Merle-Beral, H., Yamamoto, M., Dighiero, G., Davi, F., for the French Cooperative Group on CLL, (2005). The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 106: 650-657 [Abstract] [Full Text]  
• Sorror, M. L., Maris, M. B., Sandmaier, B. M., Storer, B. E., Stuart, M. J., Hegenbart, U., Agura, E., Chauncey, T. R., Leis, J., Pulsipher, M., McSweeney, P., Radich, J. P., Bredeson, C., Bruno, B., Langston, A., Loken, M. R., Al-Ali, H., Blume, K. G., Storb, R., Maloney, D. G. (2005). Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. JCO 23: 3819-3829 [Abstract] [Full Text]  
• Kienle, D. L., Korz, C., Hosch, B., Benner, A., Mertens, D., Habermann, A., Krober, A., Jager, U., Lichter, P., Dohner, H., Stilgenbauer, S. (2005). Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes. JCO 23: 3780-3792 [Abstract] [Full Text]  
• Rubio-Moscardo, F., Climent, J., Siebert, R., Piris, M. A., Martin-Subero, J. I., Nielander, I., Garcia-Conde, J., Dyer, M. J. S., Terol, M. J., Pinkel, D., Martinez-Climent, J. A. (2005). Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105: 4445-4454 [Abstract] [Full Text]  
• Calin, G. A., Trapasso, F., Shimizu, M., Dumitru, C. D., Yendamuri, S., Godwin, A. K., Ferracin, M., Bernardi, G., Chatterjee, D., Baldassarre, G., Rattan, S., Alder, H., Mabuchi, H., Shiraishi, T., Hansen, L. L., Overgaard, J., Herlea, V., Mauro, F. R., Dighiero, G., Movsas, B., Rassenti, L., Kipps, T., Baffa, R., Fusco, A., Mori, M., Russo, G., Liu, C.-G., Neuberg, D., Bullrich, F., Negrini, M., Croce, C. M. (2005). Familial Cancer Associated with a Polymorphism in ARLTS1. NEJM 352: 1667-1676 [Abstract] [Full Text]  
• Jahrsdorfer, B., Wooldridge, J. E., Blackwell, S. E., Taylor, C. M., Griffith, T. S., Link, B. K., Weiner, G. J. (2005). Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc. Biol. 77: 378-387 [Abstract] [Full Text]  
• Shanafelt, T. D., Lee, Y. K., Bone, N. D., Strege, A. K., Narayanan, V. L., Sausville, E. A., Geyer, S. M., Kaufmann, S. H., Kay, N. E. (2005). Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 105: 2099-2106 [Abstract] [Full Text]  
• Chiorazzi, N., Rai, K. R., Ferrarini, M. (2005). Chronic Lymphocytic Leukemia. NEJM 352: 804-815 [Full Text]  
• Nuckel, H., Rebmann, V., Durig, J., Duhrsen, U., Grosse-Wilde, H. (2005). HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105: 1694-1698 [Abstract] [Full Text]  
• Dighiero, G. (2005). CLL Biology and Prognosis. ASH Education Book 2005: 278-284 [Abstract] [Full Text]  
• Gribben, J. G. (2005). Salvage Therapy for CLL and the Role of Stem Cell Transplantation. ASH Education Book 2005: 292-298 [Abstract] [Full Text]  
• Pettitt, A. R., Carter, A., Lin, K., Sherrington, P. D., Atherton, M., Pearson, K., Douglas, A., Burford, A., Brito-Babapulle, V., Matutes, E., Catovsky, D. (2004). Associations between Chromosomal Aberrations and Functional Impairment of the P53 Pathway in Chronic Lymphocytic Leukaemia.. ASH ANNUAL MEETING ABSTRACTS 104: 953-953 [Abstract]  
• Rodriguez, A., Martinez, N., Camacho, F. I., Ruiz-Ballesteros, E., Algara, P., Garcia, J.-F., Menarguez, J., Alvaro, T., Fresno, M. F., Solano, F., Mollejo, M., Martin, C., Piris, M. A. (2004). Variability in the Degree of Expression of Phosphorylated I{kappa}B{alpha} in Chronic Lymphocytic Leukemia Cases With Nodal Involvement. Clin. Cancer Res. 10: 6796-6806 [Abstract] [Full Text]  
• Ritgen, M., Stilgenbauer, S., von Neuhoff, N., Humpe, A., Bruggemann, M., Pott, C., Raff, T., Krober, A., Bunjes, D., Schlenk, R., Schmitz, N., Dohner, H., Kneba, M., Dreger, P. (2004). Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104: 2600-2602 [Abstract] [Full Text]  
• Haslinger, C., Schweifer, N., Stilgenbauer, S., Dohner, H., Lichter, P., Kraut, N., Stratowa, C., Abseher, R. (2004). Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and VH Mutation Status. JCO 22: 3937-3949 [Abstract] [Full Text]  
• Montserrat, E. (2004). Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems. Ann Oncol 15: 1450-1451 [Full Text]  
• Goldin, L. R., Pfeiffer, R. M., Li, X., Hemminki, K. (2004). Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 104: 1850-1854 [Abstract] [Full Text]  
• Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A., Alizadeh, A. A., Arthur, D. C., Mitchell, J. B., Marti, G. E., Fowler, D. H., Wilson, W. H., Staudt, L. M. (2004). Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104: 1428-1434 [Abstract] [Full Text]  
• Calin, G. A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., Dell'Aquila, M. L., Alder, H., Rassenti, L., Kipps, T. J., Bullrich, F., Negrini, M., Croce, C. M. (2004). MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA 101: 11755-11760 [Abstract] [Full Text]  
• Kohlhammer, H., Schwaenen, C., Wessendorf, S., Holzmann, K., Kestler, H. A., Kienle, D., Barth, T. F. E., Moller, P., Ott, G., Kalla, J., Radlwimmer, B., Pscherer, A., Stilgenbauer, S., Dohner, H., Lichter, P., Bentz, M. (2004). Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 104: 795-801 [Abstract] [Full Text]  
• Rassidakis, G. Z., Lai, R., Herling, M., Cromwell, C., Schmitt-Graeff, A., Medeiros, L. J. (2004). Retinoblastoma Protein Is Frequently Absent or Phosphorylated in Anaplastic Large-Cell Lymphoma. Am. J. Pathol. 164: 2259-2267 [Abstract] [Full Text]  
• Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., Proffitt, J. H., Lucas, D., Grever, M. R., Byrd, J. C. (2004). Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103: 3278-3281 [Abstract] [Full Text]  
• Rush, L. J., Raval, A., Funchain, P., Johnson, A. J., Smith, L., Lucas, D. M., Bembea, M., Liu, T.-H., Heerema, N. A., Rassenti, L., Liyanarachchi, S., Davuluri, R., Byrd, J. C., Plass, C. (2004). Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets. Cancer Res. 64: 2424-2433 [Abstract] [Full Text]  
• Dreger, P., Stilgenbauer, S., Benner, A., Ritgen, M., Krober, A., Kneba, M., Schmitz, N., Dohner, H. (2004). The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103: 2850-2858 [Abstract] [Full Text]  
• Shanafelt, T. D., Geyer, S. M., Kay, N. E. (2004). Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103: 1202-1210 [Abstract] [Full Text]  
• Schwaenen, C., Nessling, M., Wessendorf, S., Salvi, T., Wrobel, G., Radlwimmer, B., Kestler, H. A., Haslinger, C., Stilgenbauer, S., Dohner, H., Bentz, M., Lichter, P. (2004). Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc. Natl. Acad. Sci. USA 101: 1039-1044 [Abstract] [Full Text]  
• Byrd, J. C., Stilgenbauer, S., Flinn, I. W. (2004). Chronic Lymphocytic Leukemia. ASH Education Book 2004: 163-183 [Abstract] [Full Text]  
• Vasconcelos, Y., Davi, F., Levy, V., Oppezzo, P., Magnac, C., Michel, A., Yamamoto, M., Pritsch, O., Merle-Beral, H., Maloum, K., Ajchenbaum-Cymbalista, F., Dighiero, G. (2003). Binet's Staging System and VH Genes Are Independent but Complementary Prognostic Indicators in Chronic Lymphocytic Leukemia. JCO 21: 3928-3932 [Abstract] [Full Text]  
• Albesiano, E., Messmer, B. T., Damle, R. N., Allen, S. L., Rai, K. R., Chiorazzi, N. (2003). Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 102: 3333-3339 [Abstract] [Full Text]  
• Kienle, D., Krober, A., Katzenberger, T., Ott, G., Leupolt, E., Barth, T. F. E., Moller, P., Benner, A., Habermann, A., Muller-Hermelink, H. K., Bentz, M., Lichter, P., Dohner, H., Stilgenbauer, S. (2003). VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 102: 3003-3009 [Abstract] [Full Text]